| Michael Wolfe, MD | |
|
2500 Metrohealth Dr, Department Of Medicine, Cleveland, OH 44109-1900 | |
| (216) 778-8266 | |
| Not Available |
| Full Name | Michael Wolfe |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Gastroenterology |
| Location | 2500 Metrohealth Dr, Cleveland, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104834753 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 350977369 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Wolfe, MD 2500 Metrohealth Dr, Department Of Medicine, Cleveland, OH 44109-1900 Ph: (216) 778-8266 | Michael Wolfe, MD 2500 Metrohealth Dr, Department Of Medicine, Cleveland, OH 44109-1900 Ph: (216) 778-8266 |
News Archive
The International Serious Adverse Events Consortium (iSAEC) announced today it will collaborate with the University of California, San Diego School of Medicine and UC San Diego Skaggs School of Pharmacy and Pharmaceutical Science to research the genetics of drug induced renal injury (DIRI).
Some specific provisions the Republican leadership plans to hold repeal votes on include the Medicare advisory panel and the CLASS Act. Meanwhile, the AMA is pointing to "war savings" as a possible way to pay for the fix to the Medicare physician payment formula.
Working as part of a public program to screen compounds to find potential medicines and other biologically useful molecules, scientists from The Scripps Research Institute and Massachusetts Institute of Technology (MIT) have discovered an extremely potent class of potential anti-cancer and anti-neurodegenerative disorder compounds.
Schiff Nutrition International, Inc., today announced results for the fiscal 2010 fourth quarter and year ended May 31, 2010.
ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.
› Verified 4 days ago
Amir Razavi, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Dr. Francois Fadell, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 18200 Lorain Ave, Moll Cancer Center At Fairview- Respiratory Institute, Cleveland, OH 44111 Phone: 216-444-6503 | |
Sana Hasan, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 Phone: 330-721-5700 | |
Catherine Frakes Vozzo, DO Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-4444 Fax: 216-445-6290 | |
Tarek Ashour, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave # Q7, Cleveland, OH 44195 Phone: 216-444-5040 | |
Mrs. Efewongbe Benedicta Oleghe, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2351 E 22nd Street, St Vincent's Charity Medical Center, Cleveland, OH 44115 Phone: 216-363-2725 | |
Dr. Toufik Z. Madhun, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave Dept Of, Cleveland, OH 44106 Phone: 216-844-1000 |